The molecular epidemiology of lung cancer

Critical Reviews in Toxicology

Volumn 27, Issue 4, 1997, Pages 319-365

  Spivack, Simon D ^a,b   Fasco, Michael J ^a   Walker, Vernon E ^a   Kaminsky, Laurence S ^a  

^a WADSWORTH CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; DNA adducts; Lung cancer; Oncogenes; Phase I metabolism; Phase II metabolism; Susceptibility; Tumor suppressor genes

Indexed keywords

CYTOCHROME; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE; XENOBIOTIC AGENT;

CANCER RISK; DNA ADDUCT; FAMILY HISTORY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LIVER MICROSOME METABOLISM; LUNG CANCER; LUNG CARCINOGENESIS; ONCOGENE; PHENOTYPE; REVIEW; TUMOR SUPPRESSOR GENE; XENOBIOTIC METABOLISM;

NICOTIANA TABACUM;

EID: 0030739591     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408449709089898     Document Type: Review

References (315)

1. US Dept. HHS, Public Health Service, NIH. NCI Bethesda, MD, Publication 91-2789. Cancer Statistics Review 1973 to 88, Eds., Gloeckler-Ries, L.A. et al.
2. Shaw, G. L., Falk, R. T., Pickle, L. W., Mason, T. J., and Buffler, P. A., Lung cancer risk associated with cancer in relatives, J. Clin. Epidemiol., 44, 429, 1991.
3. Osann, K. E., Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease, Cancer Res., 51, 4893, 1991.
4. McDuffie, H. H., Clustering of cancer in families of patients with primary lung cancer, J. Clin. Epidemiol., 44, 69, 1991.
5. Ooi, W. L., Elston, R. C., Chen, V. W., Bailey-Wilson, J. E., and Rothschild, H., Increased familial risk for lung cancer, JNCI, 2, 217, 1986.
6. Sellers, T. A., Eiston, R. C., Stewart, C., and Rothschild, H., Familial risk of cancer among randomly selected cancer probands, Genet. Epidemiol., 5, 381, 1988.
7. Liu, Z., He, X., and Chapman, R. S., Smoking and other risk factors for lung cancer in Xuanwei, China, Int. J. Epidemiol., 21, 26, 1991.
8. Samet, J. M., Humble, C. G., and Pathak, D. R., Personal and family history of respiratory disease and lung cancer risk, Am. Rev. Respir. Dis., 134, 466, 1986.
9. Braun, M. M., Caporaso, N. E., Page, W. F., and Hoover, R. N., Genetic component of lung cancer: cohort study of twins, Lancet, 344, 440, 1994.
10. Braun, M. M., Caporaso, N. E., Page, W. F., and Hoover, R. N., A cohort study of twins and cancer, Cancer Epidemiol. Biomark. Prev., 4, 469, 1995.
11. Olsen, J. H., Boice, J. D., Seersholm, N., Bautz, A., and Fraumeni, J. F., Cancer in the parents of children with cancer, N. Engl. J. Med., 333, 1594, 1995.
12. Sorensen, T. I. A., Is there an inherited general susceptibility to cancer?, N. Engl. J. Med., 333, 1633, 1995.
13. Mulshine, J. L., Linnoila, R. I., Jensen, S. M., Magnani, J. L., Tockman, M. S., Gupta, P. K., Scott, F. S., Avis, I., Quinn, K., Birrer, M. J. et al., Rational targets for the early detection of lung cancer, Monographs - National Cancer Institute, 13, 183, 1992.
14. Tockman, M. S., Gupta, P. K., Pressman, N. J., and Mulshine, J. L., Cytometric validation of immunocytochemical observations in developing lung cancer, Diagn. Cytopathol., 9(6), 615, 1993.
15. Mao, L., Lee, D. J., Tockman, M. S., Erozan, Y. S., Askin, F., and Sidransky, D., Microsatellite alterations as clonal markers for the detection of human cancer, Proc. Natl. Acad. Sci. U.S.A., 91(21), 9871, 1994.
16. Perera, F., Molecular cancer epidemiology: a new tool in cancer prevention, JNCI, 78, 887, 1987.
17. Ware, J. and Neumann, D., On repeated measures, Personal communication, Harvard SPH, 8/9/96.
18. Wyllie, A. H., Apoptosis, Br. J. Cancer, 67, 205, 1993.
19. Robbins, S. L., Cotran, R. S., and Kumar, V., The Pathologic Basis of Disease, 4th ed., Saunders, Philadelphia, 1989.
20. Jacobson, D. R., Fishman, C. L., and Mills, N. E., Molecular genetic tumor markers in the early diagnosis and screening of non-small lung cancer, Ann. Oncol, 6(Suppl. 3), S3, 1995.
21. Idle, J. R., Is environmental carcinogenesis modulated by host polymorphism?, Mutat Res., 247, 259, 1991.
22. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., and Hayashi, S., The CYPIAI gene and cancer susceptibility, Crit. Rev. Oncol. Hematol., 14, 77, 1993.
23. Guengerich, F. P., Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy, Cancer Res., 48, 2946, 1988.
24. Wheeler, C. W. and Guenther, T. M., Cytochrome P450-dependent metabolism of xenobiotics in human lung, J. Biochem. Toxicol., 6, 163, 1991.
25. Amos, C. J., Caporaso, N. E., and Western A., Host factors in lung cancer risk: a review of interdisciplinary studies, Cancer Epidemiol. Biomarkers Prevention, 1, 505, 1992.
26. Swanson, H. I. and Bradfield, C. A., The Ah receptor, genetics, structure and function, Pharmacogenetics, 3, 213, 1993.
27. Hayashi, S., Watanabe, J., Nakachi, K., Eguchi, H., Gotoh, O., and Kawajiri, K., Interindividual difference in expression of human Ahr and related P450 genes, Carcinogenesis, 15, 801, 1994.
28. Itoh, S. and Kamataki, T., Human Ah receptor cDNA: analysis for highly conserved sequences, Nucl. Acids Res., 21, 3578, 1993.
29. Fujii-Kuriyama, Y., Ema, M., Mimura, J., Matsushita, N., and Sogawa, K., Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene, Pharmacogenetics, 5, S149, 1995.
30. Kawajiri, K., Watanabe, J., Eguchi, H., Nakachi, K., Kiyohara, C., and Hayashi, S., Polymorphisms of human Ah receptor gene are not involved in lung cancer, Pharmacogenetics, 5, 151, 1995.
31. Miller, E. C. and Miller, J. A., Search for ultimate chemical carcinogens and their reactions with cellular macromolecules, Cancer, 47, 2327, 1981.
32. Devereux, T. R., Domin, B. A., and Philpot, R. M., Xenobiotic metabolism by isolated pulmonary cells, Pharmacol. Ther., 41, 243, 1989.
33. Jeffrey, A. M., Weinstein, I. B., Jennette, K. W., Grzeskowiak, K., Nakanishi, K., Harvey, R. G., Autrup, H., and Harris, C., Structures of benzo[a]pyrene-nucleic acid adducts formed in human and bovine bronchial explants, Nature, 269, 348, 1977.
34. Karki, N. T., Pokels, R. Neutice, L., and Pekonen, O., Arylhydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls, Int. J. Cancer, 39, 565, 1987.
35. Devereux, T. R., Massey, T. E. VanScott, M. R., Yankaskas, J., and Fouts, J. R., Xenobiotic metabolism in human alveolar type II cells isolated by centrifuged elutriation, density gradient centrifugation, Cancer Res., 46, 5438, 1986.
36. Harris, C. C., Autrup, H., Connor, R. D., Barrett, L. A., McDowell, E. M., and Trump, B. F., Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi, Science, 194, 1067, 1976.
37. Wheeler, C. W., Park, S. S., and Guenthner, T. M., Immunochemical analysis of a cytochrome P-450IA1 homologue in human lung microsomes. Mol. Pharmacol., 38, 634, 1990.
38. Rojas, M., Camus, A. M., Alexandrov, K., and Husgafvel-Pursiainen, Stereoselective metabolism of (-) benzo[a]-pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking, Carcinogenesis, 13(6), 929, 1992.
39. Fasco, M. J., Treanor, C. P., Spivack, S., Figge, H., and Kaminsky, L. S., Quantitative RNA-polymerase chain reaction-DNA analysis by capillary electrophoresis and laser-induced fluorescence, Anal. Biochem., 224, 140, 1995.
40. Nakajima, T., Elovaara, E., Anttila, S., Hirvonen, A., Camus, A. M., Hayes, J. D., Ketterer, B., and Vainio, H., Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer, Carcinogenesis, 16(4), 707, 1995.
41. 3H-tetrachlorodibenzo-p-dioxin, Cancer Res., 46, 3739, 1986.
42. Cantrell, E. T., Parr, G. A., Buebic, D. C., and Martin, R. R., Induction of AHH human pulmonary alvelor macrophages by cigarette smoke, J. Clin. Invest., 52, 1881, 1973.
43. Kellerman, G., Shaw, C. R., and Lufer-Kellerman, M., AHH inducibility and bronchogenic carcinoma, N. Engl. J. Med., 289, 93, 1973.
44. Kouri, R. E., McKinney, C. E., Slomiany, D. J., Snodgrass, D. R., Wray, N. P., and McLemore, T. L., Positive correlation between high AHH activity and primary lung cancer as analyzed in cryopreserved lymphocytes, Cancer Res., 42, 5030, 1982.
45. Petruzelli, S., Camus, A. M., Carrozzi, L., Ghelarducci, L., Rindi, M., Menconi, G., Angeletti, C. A., Ahotupa, M., Hietanen, E., and Aitio, A., Long-lasting effects of tobacco smoking on pulmonary drug and metabolizing enzymes: a case-control study on lung cancer patients, Cancer Res., 48, 4695, 1988.
46. Bartsch, H., Petruzzelli, S., and DeFlora, S., Carcinogen metabolism in human lung tissues and the effect of tobacco smoking, Environ. Health Persp., 4(98), 119, 1992.
47. Kouri, R. E., Billups, L. H., Rude, T. H., Whitmire, C. E., Sass, B., and Henry, C. J., Correlation of inducibility of AHH with susceptibility to 3-methycholanthrene-induced lung cancers, Cancer Lett., 9, 277, 1980.
48. Kouri, R. E., McKinney, C. E., Levine A. S., Edwards, B. K., Vesell, E. S., Nebert, D. W., and McLemore, T. L., Variations in AHH activities in mitogen-activated human and nonhuman primate lymphocyte, Toxicol. Pathol., 12, 44, 1984.
49. Omiecinski, C. J., Redlich, C. A., and Costa, P., Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction, Cancer Res., 50, 4315, 1990.
50. McLemore, T. L., Adelberg, S., Liu, M. C., McMahon, N. A., Yu, S. J., Hubbard, W. C., Czerwinski, M., Wood, T. G., Storeng, R., and Lubet, R. A., Expression of CYP1A1 gene in patients with lung cancer, J. Natl. Cancer Inst., 82, 1333, 1990.
51. Cosma, G. N., Toniolo, P., Currie, D., Pasternack, B. S., and Garte, S. J., Expression of CYP1A1 gene in peripheral lymphocytes as a marker of exposure to creosote in railroad workers, Cancer Epid. Biom. Prev., 1, 137, 1992.
52. Vanden Heuvel, J. P., Clark, G. C., and Thompson, C. L., CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative RT-PCR to measure CYP1A1 expression in human peripheral blood lymphocytes, Carcinogenesis, 1, 2003, 1993.
53. Petersen, D. D., McKinney, C. E., Ikeya, K., Smith, H. H., Bale, A. E., McBride, O. W., and Nebert, D. W., Human CYP1A1 gene: co-segregation of the enzyme inducibility phenotype and an RFLP, Am. J. Hum. Genet., 48, 720, 1991.
54. Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N., and Watanabe, J., Identification of genetically high-risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene, FEBS Lett., 263, 131, 1990.
55. Cosma, G., Crofts, F., Currie, D., Wirgin, I., Toniolo, P., and Garte, S. J., Racial differences in RFLPs and mRNA inducibility of the human CYP1A1 gene, Cancer Epidemiol. Biomed. Prev., 3, 53, 1993.
56. Crofts, F., Taioli, E., Trachman, J., Cosma, G. N., Currie, D., Toniolo, P., and Garte, S. J., Functional significance of different human CYP1A1 genotypes, Carcinogenesis, 15, 2961, 1994.
57. Landi, M. T., Bertazzi, P. A., Shields, P. G., Clark, G., Lucier, G. W., Garte, S. J., Cosma, G., and Caporaso, N. E., Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans, Pharmacogenetics, 4, 242, 1994.
58. Kawamoto, T., Koga, M., Murata, K., Matsuda, S., and Kodama, Y., Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans, Tox. Appl. Pharmacol., 133, 295, 1995.
59. Hayashi, S., Watanabe, J., Nakachi, K., and Kawajiri, K., Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene, J. Biochem.(Tokyo), 110, 407, 1991.
60. Hayashi, S., Watanabe, J., and Kawajiri, K., High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and mu-class glutathione S-tranferase genes, Jpn. J. Cancer Res., 83, 866, 1992.
61. Sugimura, H., Suzuki, I., Hamada, G. S., Iwase, T., Takahashi, T., Nagura, K., Iwata, H., Watanabe, S., Kino, I., and Tsugane, S., Cytochrome P450 IA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil, Cancer Epidemiol. Biomed. Prev., 3, 145, 1994.
62. Hirvonen, A., Husgafvel-Pursiainen, K., Karjalainen, A., Anttila, S., and Vainio H., Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population, Cancer Epidemiol. Biomarkers Prev., 1, 485, 1992.
63. Drakoulis, N., Cascorbi, I., Brockmoller, J., Gross, C. R., and Roots, I., Polymorphisms in the human CYP1A1 gene as a susceptibility factor for lung cancer, Clin. Invest., 72, 240, 1994.
64. Shields, P. G., Caporaso, N. E., Falk, R. T., Sugimura, H., Trivers, G. E., Trump, B. F., Hoover, R. N., Weston, A., and Harris, C. C., Lung cancer, race, and a CYP1A1 genetic polymorphism, Cancer Epidem. Biomarkers Prev., 2, 481, 1993.
65. Tefre, T., Ryberg, D., Haugen, A., Nebert, D. W., Skaug, V., Brogger, A., and Borresen, A. L., Human CYP1A1 gene: lack of association between the MSP1 restriction fragment length polymorphisms and incidence of lung cancer in a Norwegian population, Pharmacogenetics, 1, 20, 1991.
66. Shields, P. G., Bowman, E. D., and Harrington, A. M., Polycycle aromatic hydrocarbon DNA adducts in human lung and cancer susceptiblity genes, Cancer Res., 53, 3486, 1993.
67. Hamada, G. S., Sugimura, H., Suzuki, I., Nagura, K., Kiyokawa, E., Iwase, T., Tanaka, M., Takahashi, T., Watanable, S., and Kino, I., The heme-binding region of CYP1A1, rather than the Rsa polymorphism of CYP2E1, is associated with lung cancer in Rio de Janeiro, Cancer Epid. Biom. Prev., 4, 63, 1995.
68. London, S. J., Daly, A. J., Fairbrother, K. S., Holmes, C., Carpenter, C. L., Navidi, W. C., and Idle, J. R., Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism, Cancer Res., 55, 6035, 1995.
69. Taoli, E., Crofts, F., Trachman, J., Demopoulos, R., Toniolo, P., and Garte, S. J., A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung, Cancer Res., 55, 472, 1995.
70. Gonzalez, F. J. and Gelboin, H. V., Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins, Drug Metab. Rev., 26, 165, 1994.
71. Smith, C. A. D., Moss, J. E., and Gough, A. C., Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility, Environ. Health Persp., 98, 107, 1992.
72. Smith, T. J., Guo, Z., Gonzalez, F., Guengerich, F. P., Stoner, G. D., and Yang, C. S., Metabolism of 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone in human lung and liver microsomes and cytochromes P450 expressed in hepatoma cells. Cancer Res., 52, 1757, 1992.
73. Crespi, C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. J., A tobacco smoke derived nitrosamine, 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic cytochrome P4502D6, Carcinogenesis, 12, 1197, 1991.
74. Penman, B. W., Reece, J., Smith, T., Yang, C. S., Gelboin, H. V., Gonzalez, F. J., and Crespi, C. L., Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6 locus, Nature, 347, 773, 1990.
75. Widersten, M., Pearson, W. R., Engstrom, A., and Mannerik, B., Heterologous expression of the allelic variant m-class glutathione transferases μ and x, Biochem. J., 276, 519, 1991.
76. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R., Metabolic oxidation phenotypes as markers for susceptibility to lung cancer, Nature, 32, 169, 1984.
77. Law, M. R., Hetzel, M. R., and Idle, J. R., Debrisoquine metabolism and genetic predisposition to lung cancer, Br. J. Cancer. 59, 686, 1989.
78. Harris, C. C., Westor, A., and Willey, J. C., Biochemical and molecular epidemiology of human cancer, in Microsomes and Drug Oxidations, Birkett, D. J., Ed., Proceedings of the 7th International Symposium, Taylor & Francis, London, 1988.
79. Caporaso, N. E., Tucker, M. A., Hoover, R. N., Hayes, R. B., Pickle, L. W., Issaq, H. J., Muschik, G. M., Green-Gallo, L., Buivys, D., and Aisner, S., Lung cancer and the debrisoquine metabolic phenotype, J. Natl. Cancer Inst., 82, 1264, 1990.
80. Agundez, J. A. G., Martinez, C., Ladero, J. M., Ledesma, M. C., Ramos, J. M., Martin, R., Rodruguez, A., Jara, C., and Benitez, J., Debrisoquine oxidative genotype and susceptibility to lung cancer, Clin. Pharm. Ther., 55, 10, 1994.
81. Bouchardy, C., Benhamou, S., and Dayer, P., The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res., 56, 251, 1996.
82. Broly, F. and Meyer, U. A., Debrisoquine oxidation polymorphism: phenotypic consequences of a 3 base pair deletion in exon 5 of the CYP206 gene, Pharmacogenetics, 3, 123, 1993.
83. Rannug, A., Alexandrie, A-K., Persson, I., and Ingelman-Sundberg, M., Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance, J. Occpat. Environ. Med., 37(1), 25, 1995.
84. Drakoulis, N., Minks, T., and Ploch, M., Questionable association of debrisoquine hydroxlator phenotype and risk for bronchiol carcinoma, Acta. Pharmacol. Toxicol., 59, 220, 1986.
85. Benitez, J., Ladero, J. M., Jara, C., Carrillo, J. A., Cobaleda, J., Llerena, A., Vargas, E., and Munoz, J. J., Polymorphic oxidation of debrisoquine in lung cancer patients, Eur. J. Cancer, 27, 158, 1991.
86. Duche, J. C., Joanne, C., Barre, J., de Cremoux, H., Dalphin, J. C., Depierre, A., Brochard, P., Tillement, J. P., and Bechtel, P., Lack of relationship between the polymorphism of debrisoquire oxidation and lung cancer, Br. J. Clin. Pharmacol., 31, 533, 1991.
87. Stucker, I., Cosme, J., Laurent, P. H., Cenee, S., Beaune, P. H., Bigman, J., Depierre, A., Milleron, B., and Hemon, D., CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure, Carcinogenesis, 16(11), 2759, 1995.
88. Shaw, G. L., Falk, R. T., Deslauriers, J., Frame, J. N., Nesbitt, J. C, Pass, H. L, Issaq, H. J., Hoover, R. N., and Tucker, M. A., Debrisoquine metabolism and lung cancer, Cancer Epid. Biom. Prev., 4, 41, 1995.
89. Ingleman-Sundberg, M., Johnson, I., and Perrson, I., Genetic polymorphism of cytochromes P450. Interethnic differences and relationsip to incidence of lung cancer, Pharmacogenetics, 2, 264, 1992.
90. Bertilsson, L., Lou, Y. Q., Du, Y. L., Liu, Y., Kuang, T. Y., Liao, X. M., Wang, K. Y., Reviriego, J., Iselius, L., and Sjoqvist, F., Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mepheytoin, Clin. Pharmacol. Ther., 51, 388, 1992.
91. Sugimura, H., Caporaso, N., Shaw, G. L., Modali, R. V., Gonzalez, F. J., Hoover, R. N., Resau, J. H., Trump, B. F., Weston, A., and Harris, C. C., Human debrisoquine hydroxylase gene polymorphisms in cancer populations and controls, Carcinogenesis, 11, 1527, 1990.
92. Gough, A. C., Miles, J. S., Spurr, M. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., and Wolf, C. R., Identification of the primary gene deficit at the cytochrome P450 CYP2D locus, Nature, 347, 773, 1990.
93. Heim, M. and Meyter, U. A. Genotyping poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529, 1990.
94. Caporaso, N. E., Shields, P. G., Landi, M. T., Shaw, G. L., Tucker, M. A., Hoover, R., Sugimura, H., Weston, A., and Harris, C. C., The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification, Environ. Health Persp., 98, 101, 1992.
95. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Pelkonen, O., and Vainio, H., PCR-based CYP2D6 genotyping for Finnish lung cancer patients, Pharmacogenetics, 3, 19, 1993.
96. Tyndale, T., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H. V., Meyer, U. A., and Gonzalez, F. J., Identification of a new variant of CYP2D6 allele lacking the codon encody Lys-281: possible association with poor metabolize phenotype, Pharmacogenetics, 1, 26, 1991.
97. Broly, F., Gaedigk, A., Heim, M., Eichelbaum, M., Morike, K., and Meyer, U. A., Debrisoquine/spartane hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population, DNA Cell Biol., 8, 545, 1991.
98. Dahl, M. L., Johansson, I., Palmertz, M. P., Ingelman-Sundberg, M., and Sjoqvist, F., Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population, Clin. Pharmacol Ther., 51, 12, 1992.
99. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R., and Watanabe, M., Association between RFLP of the human cytochrome P4502E1 gene and susceptibility to lung cancer, Jpn. J. Cancer Res., 82, 254, 1991.
100. Persson, I., Johansson, I., Bergung, H., Dahl, M-L., Seidegard, J., Rylander, R., Rannug, A., Hogberg, J., and Sundberg, M. I., Genetic polymorphism of cytochrome P4502E1 in a Swedish population: relationship to incidence of lung cancer, FEBS Lett., 319(3), 207, 1993.
101. Hirvonen, A., Husgafvel-Pursiainen, K., Anttilo, S., Karjalainen, A., and Vainio, H., The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population, Carcinogenesis, 14(1), 85, 1993.
102. Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., Weston, A., and Harris, C. C., Cytochrome P4502E1 genetic polymorphisms, racial variation and lung cancer risk, Cancer Res, 52, 6712, 1992.
103. Hamada, G., S., Sugimura, H., Suzuki, I., Nagura, K., Kiyokawa, E., Iwase, T., Tanaka, M., Takahashi, T., Watanabe, S., and Kino, I., The heme-binding region polymorphism of cytochrome P4501A1 (CYP1A1), rather than the RsaI polymorphism of 2E1 (CYP2E1), is associated with lung cancer in Rio de Janeiro, Cancer Epid. Biom. Prev., 4, 63, 1995.
104. Hildesheim, A., Chen, C. J., Caporaso, N. E., and Cheng, Y. J., Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan, Cancer Epid. Biom. Prev., 4, 607, 1995.
105. Ketterer, B., Harris, J. M., Talaska, G., Meyer, D. J., Pemble, S. E., Taylor, J. B., Lang, N. P., and Kadlubar, F. F., The human glutathione S-transferase supergene family, its polymorphisms, and its effects on susceptibility to lung cancer. Environ. Health Persp., 98, 87, 1992.
106. Daly, A. K., Cholerton, S., Armstrong, M., and Idle, J. R., Genotyping for polymorphisms in xenobiotic metabolism as a prediction of disease susceptibility. Environ. Health Persp., 102, 55, 1994.
107. Kensler, T. W., Egner, P. A, Davidson, N. E., Roebuck, B. D., Pikul, A., and Groopman, J. D., Modulation of aflatoxin metabolism, aflatoxin N7-guanyl formation and hepatic tumorigenesis in rats fed ethoxyquine: role of induction of glutathione S-transferases, Cancer Res., 46, 3924, 1986.
108. 32P-postlabeling assay, J. Natl. Cancer Inst., 81, 341, 1989.
109. Pinkus, R., Weiner, L. M., and Daniel, V., Role of quinone-mediated generation of hydroxyl radicals in the induction of glutathione S-transferase gene expression, Biochemistry, 34, 81, 1995.
110. Jaiswal, A. K., Antioxidant response element, Biochem. Pharmacol., 48, 439, 1994.
111. Brockmoller, J., Kerb, R., Drakoulis, N., Nitz, M., and Roots, I., Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and x in lung cancer patients and controls. Cancer Res., 53, 1004, 1993.
112. Heckbert, S. R., Weiss, N. S., Hornung, S. K., Eaton, D. L., and Motulsky, A. G., Glutathione S-transferase and expoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers, J. Natl. Cancer Inst., 84, 414, 1992.
113. Soni, M. G., Krishna, T. P., and Krishnaswamy, K., Human leukocyte glutathione S-transferase isozyme (class mu) and susceptibility to smoking-related cancers, J. Tox. Environ. Health, 46, 1, 1995.
114. Nijhoff, W. A., Grubben, J. A. L., Nagengast, F. M., Jansen, J. B., Verhagen, H., Van Poppel, G., and Peters, W. H., Effects of consumption of Brussels sprouts on intestinal and lymphocytic glutathione S-transferases in humans, Carcinogenesis, 16(9), 2125, 1995.
115. Offord, E. A., Mace, K., Ruffieux, Malnoe, A., and Pfeifer, A. M. A., Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells, Carcinogenesis, 16(9), 2057, 1995.
116. Seidegard, J., Varachek, W. R., Pero, R. W., and Pearson, W. R., Hereditary differences in the expression of the human glutathione S-transferase active on trans-stilbene oxide are due to a gene deletion, PNAS, 85, 7293, 1988.
117. Fryer, A. A., Zhao, L., Alldersea, J., Boggild, M. D., Perrett, C. W., Clayton, R. N., Jones, P. W., and Strange, R. C., The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1*0 genotype in patients with pituitary adenomas, Carcinogenesis, 14, 563, 1993.
118. Bell, D. A., Thompson, C. L., Taylor, J., Miller, C. R., Perera, F., Hsieh, L. L., and Lucier, G. W., Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase μ, Environ. Health Persp., 98, 113, 1992.
119. Shields, P. G., Baumen, E. D., and Harrington, A. M., Polycycle aromatic hydrocarbon DNA adducts in human lung and cancer susceptibility genes, Cancer Res., 53, 3486, 1993.
120. Ryberg, D., Hewer, A., Phillips, D. H., and Haugen, A., Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients, Cancer Res., 54, 5801, 1994.
121. Kato S., Bowman E., Harrington A., Blomeke, B., and Shields, P. G., Human lung carcinogen-DNA adductlevels mediated by genetic polymorphisms in vivo, JNCI, 87(12), 902.
122. Cheng, T. J., Christiani, D. C., Xu, X., Wain, J. C., Wiencke, J. K., and Kelsey, K. T., Glutathione S-transferase μ genotype, diet and smoking as determinants of sister chromatid exchange frequency in lymphocytes, Cancer Epid. Biom. Prev., 4, 535, 1995.
123. Wiencke, J. K., Pemble, S., Ketterer, B., and Kelsey, K. T., Gene deletion of glutathione S- transferase θ: correlation with induced genetic damage and potential role in endogenous mutagenesis, Cancer Epid. Biom. Prev., 4, 253, 1995.
124. Ryberg, D., Kure, E., Lystad, S., Skaug, V., Stangeland, L., Mercy, I., Borresen, A. L., and Haugen, A., p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer, Cancer Res., 54, 1551, 1994.
125. Seidegard, J. Peru, R. W., Markowitz, M. M., Roush, G., Miller, D. G., and Beattie, E. J., Isozymes of glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: a follow-up study, Carcinogenesis, 11, 33, 1990.
126. Zhong, S., Howie, A. F., Ketterer, B., Taylor, J., Hayes, J. D., Beckett, G. J., Wathen, C. G., Wolf, C. R., and Spurr, N. K., Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility, Carcinogenesis, 12, 1533, 1991.
127. Kihara, M., Noda, K., and Kihara, M., Distribution of GSTM1 null genotype in relation to gender, age, and smoking status in Japanese lung cancer patients, Pharmacogenetics, 5, S74, 1995.
128. Hirvonen, A., Husgafvel-Puriainen, K., Anttila, S., and Vainio, H., The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung, Carcinogenesis, 14, 1479, 1993.
129. Nazar-Stewart, V., Motulsky, A. G., Eaton, D. L., White, E., Hornung, S. K., Leng, Z. T., Stapleton, P., and Weiss, N. S., The glutathione S-transferase μ polymorphism as a marker for susceptibility to lung carcinoma, Cancer Res., 53, 2313, 1993.
130. Kawajiri, K., Watanabe, J., Eguchi, H., and Hayashi, S., Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility, Pharmacogenetics, 5, S70, 1995.
131. Nakachi, K., Imai, K., Hayashi, S., and Kawejiri, K., Polymorphisms of the CYP1A1 and GST genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population, Cancer Res., 53, 2994, 1993.
132. Alexandrie, A. K., Sundberg, M. I., Seidegard, J., Tornling, G., and Rannug, A., Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1, Carcinogenesis, 15(9), 1785, 1995.
133. McWilliams, J. E., Sanderson, B. J. S., Harris, E. L., Richert-Boe, K. E., and Henner, W. D., Glutathione S-transferase M1 deficiency and lung cancer risk. Cancer Epid. Biom. Prev., 4, 589, 1995.
134. Lafuente, A., Pujol, F., Carretero, P., Villa, J. P., and Cuchi, A., Human glutathione S-transferase μ gene deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett., 68, 49, 1993.
135. Bell, D. A., Taylor, J. A., Paulson, D. F, Robertson, C. N., Mohler, J. L., and Lucier, G. W., Genetic risk and carcinogen exposure: a common inherited defect of carcinogen-metabolism gene glutathione S-transferase M1 that increases susceptibility to bladder carcinoma, JNCI, 85, 1159, 1993.
136. Zhong, S., Wyllie, A. H., Barnes, D., Wolf, C. R., and Spurr, N. K., Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer, Carcinogenesis, 14, 1821, 1993.
137. Powis, G., Free radical formation by antitumor quinoes, Free Rad. Biol. Med., 6, 63, 1989.
138. Fisher, G. R., Patterson, L. H., and Gutierrez, P. L., A comparison of free radical formation by quinone antitumor agents in MCF-7 cells and the role of NAD(P)H:(Quinone-Acceptor) oxidoreductase (DT-Diaphorase), Chem. Biol. Interaction, 137, 1993.
139. Nutler, L. M., Ngo, E. O., Fisher, G., and Gutierrez, P. L., DNA-strand scission and free radical production in menadane-treated cells, J. Biol. Chem., 267, 2474, 1992.
140. Chesis, P. L., Levin, D. E., Smith, M. T., Ernster, L., and Ames, B. N., Mutagenicity of quinones: pathways of metabolic activation and detoxification, PNAS, 81, 1696, 1984.
141. Schlager, J. J. and Powis, G., Cytoslic NAD(P)H: (Quinone-Acceptor) oxidoreductase in human normal and tumor tissue. Effects of cigarette smoking and alcohol, Int. J. Cancer, 45, 403, 1990.
142. Offord, E. A., Mace, K., Ruffieux, Malnoe, A., and Pfeifer, A. M. A., Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells, Carcinogenesis, 16(9), 2057, 1995.
143. Edwards, T. H., Potter, J., and Hopkins, D. A., Human FAD-dependent NAD(P)H diaphorase, Biochem. J., 187, 429, 1985.
144. Belinsky, M. and Jaiswal, A. K., NAD(P)H: Quinone oxidoreductase, (DT-diaphorase) expression in normal and tumor tissues, Cancer Metastasis Rev., 12, 103, 1993.
145. Rushmore, T. H., Morton, M., and Pickett, C. B., The antioxide responsive element, J. Biol. Chem., 266, 11632, 1991.
146. 2 gene locus in chromosome 6, Biochemistry, 29, 1899, 1990.
147. Siegel, D., Traver, R. D., and Beall, H. D., Cloning and purification of a mutant DT-diaphorase protein from human colon and lung cancer cell lines, Proc. Am. Assoc. Cancer Res., 36, 1729, 1995.
148. Nakachi, K., Imai, K., Hayashi, S., and Kawejiri, K., Polymorphisms of the CYP1A1 and GST genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population, Cancer Res., 53, 2994, 1993.
149. Kihara, M., Kihara, M., and Noda, K., Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population, Carcinogenesis, 16(10), 2331, 1995.
150. Kato, S., Bowman, E., Harrington, A., Blomeke, B., and Shields, P. G., Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo, J. Natl. Cancer Inst., 87(12), 902.
151. Marnett, L. J. and Burcham, P. C., Alkylation damage, DNA repair, and mutagenesis in human cells, Chem. Res. Toxicol., 6, 771, 1993.
152. Phillips, D. H., Schoket, B., Hewer, A., Bailey, E., Kostic, S., and Vincze, I., Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells, Int. J. Cancer, 46, 569, 1990.
153. Cuzick, J., Routledge, M. N, Jenkins, D., and Garner, R. C., DNA adducts in different tissues of smokers and non-smokers, Int. J. Cancer, 45, 673, 1990.
154. Dunn, B. P., Vedal, S., San, R. H. C, Kwan, W. F, Nelems, B., Enarson, B., and Stich, H. F., DNA adducts in bronchial biopsies. Int. J. Cancer, 48, 485, 1991.
155. 32P-postlabeling: metabolic phenotype dependence and comparison with other exposure markers, in Postlabeling Methods for Detection of DNA Products, Phillips, D. H., Castegnaro, M., and Bartsch, H., Eds., IARC, Lyons, 331, 1993.
156. Philips, D. H., Hewer, A., Martin, C. M., Garner, R. C., and King, M. M., Correlation of DNA adduct levels in human lung with cigarette smoking, Nature, 336, 790, 1988.
157. VanSchooten, F. J., Hillebrand, M. J. X., Van Leeuwen, F. E., Lutgerink, J. T., Van Zandwijk, N., Jansen, H. M., and Kriek, E., PAH-DNA of adducts in lung tissue from lung cancer patients, Carcinogenesis, 11, 1677, 1990.
158. Perera, F., Mayer, J., Jaretzki, A., Hearne, S., Brenner, D., Young, T. L., Fischman, H. K., Grimes, M., Grantham, S., and Tang, M. X., Comparison of DNA adducts and sister chromatid exchange in lung cancer cases and controls, Cancer Res., 49, 4446, 1989.
159. Weston, A., Bowman, E. D., Shields, P. G., Trivers, G. E., Poirier, M. C., Santella, R. M., and Manchester, D. K., Detection of polycyclic aromatic hydrocarbon-DNA adducts in human lung, Environ. Health Persp. 99, 257, 1993.
160. Tang, D., Santella, R. M., Blackwood, A. M., Young, T. L., Mayer, J., Jaretzki, A., Grantham, S., Tsai, W. Y., and Perera, F. P., A molecular epidemiological case-control study of lung cancer, Cancer Epid. Biom. Prev., 4, 341, 1995.
161. Shields, P. G., Bowman, E. D., and Harrington, A. M., Polycycle aromatic hydrocarbon DNA adducts in human lung and cancer susceptiblity genes, Cancer Res., 53, 3486, 1993.
162. Stern, S. J., Degawa, M., Martin, M. V., Guengerich, F. P., Kaderlik, R. K., Hett, K. F., Breau, R., McGhee, M., Montague, D., and Lyn-Cook, B., Metabolic activation, DNA adducts and h-ras mutations in human neoplastic and non-neoplastic laryngeal tissue, J. Cell Biochem. Suppl., 17F, 129, 1993.
163. VanSchooten, F. J., Hillebrand, M. J. X., Van Leeuwen, F. E., Van Zandwijk, N., Jansen, H. M., Den Engelse, L., and Kriek, E., PAH-DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels, Carcinogenesis, 13, 987, 1992.
164. 32P-Postlabeling analysis of DNA adducts in different populations, Toxicol. Lett., 77, 299, 1995.
165. 32P-postlabeling assay, Carcinogenesis, 12(3), 503, 1991.
166. 32P-postlabeling in human lymphocytes and granulocytes, Env. Health Persp., 101(Suppl. 3), 145, 1993.
167. Mooney, L. A., Santella, R. M., Covey, L., Jeffrey, A. M., Bigbee W., Randall M. C., Cooper T. B., Ottman R., Tsai W. Y., and Wazneh L., Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation, Cancer Epid. Biom. Prev., 4, 627, 1995.
168. Santella, R. M., Grinberg-Funes, R. A., Young, T. L., Dickey, C., Singh, V. N., Wang, L. W., and Perera, F. P., Cigarette smoking-related polycyclic aromatic hydrocarbon-DNA adducts in peripheral mononuclear cells, Carcinogenesis, 13, 2041, 1992.
169. Van Schooten, F. J., Jongeneelen, F. J., Hillebrand, M. J. X., Van Leeuwen, F. E., De Looff, A. J., Dijkmans, A. P., Van Rooij, J. G., Den Engelse, L., and Kriek, E., Polycyclic aromatic hydrocarbon-DNA adducts in white blood cell DNA and 1-hydroxypyrene in the urine from aluminum workers: relation with job category with synergistic effect of smoking, Cancer Epid. Biom. Prev., 4, 69, 1995.
170. Perera, F. P., Santella, R. M., and Brenner, D., DNA adducts, protein adducts and sister chromatid exchange in cigarette smokers and non-smokers, JNCI, 79, 449, 1987.
171. Philips, D. H., Schoket, B., Hewer, A., Bailey, E., Kostic, S., and Vincze, I., Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells, Int. J. Cancer, 46, 569, 1990.
172. Van Maaner, J. M. S., Maas, L. J., Hagema, G., Kleinjans, J. C., and van Agen, B., DNA adduct and mutation analysis in WBCs of smokers and nonsmokers. Environ. Mol. Mut., 24, 46, 1994.
173. Van Maanen, J. M. S., Moonen, E. J. C., Maas, L. M., Kleinjans, J. C. S., and van Schooten, F. J., Formation of aromatic DNA adducts in white blood cells in relation to urinary excretion of 1-hydroxypyrene during consumption of grilled meat, Carcinogenesis, 15(10), 2263.
174. Rothman, N., Poirer, M. C., Haas, R. A., Correa-Villasenor, A., Ford, P., Hansen, J. A., O'Toole, T., and Stickland, P. T., Association of PAH-DNA adducts in peripheral WBCs with dietary exposure to PAHs, Environ. Health Persp., 99, 265, 1993.
175. Rothman, N., Correa-Villasenor, A., Ford, D. P., Poirier, M. C., Haas, R., Hansen, J. A., O'Toole, T., and Strickland, P. T., Contribution of occupation and diet to white blood cell polycyclic aromatic hydrocarbon-DNA adducts in wildland firefighters. Cancer Epid. Biom. Prev. 2, 341, 1993.
176. Kriek, E., Van Schoeten, F. J., Hillebrand, M. J. X., Van Leeuwen, F. E., Den Engelse, L., De Loof, A. J., and Dijkmans, A. P., DNA adducts as a measure of lung cancer risk in humans exposed to PAH, Environ. Health Persp., 99, 71, 1993.
177. Hemminki, K., Gryzbowska, E., Chorazy, M., Twardowska-Saucha, K., Sroczynski, J. W., Putman, K. L., Randerath, K., Phillips, D. H., Hewer, A., and Santella, R. M., DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland, Carcinogenesix, 11(7), 1229, 1990.
178. Hemminki, K., Gryzbowska, E., Chorazy, M., Twardowska-Saucha, K., Sroczynski, J. W., Putman, K. L., Randerath, K., Phillips, D. H., Hewer, A., and Santella, R. M., DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland, Carcinogenesix. 11(7), 1229, 1990.
179. Kawajiri, K., Eguchi, H., Nakachi, K., Sekiya, T., and Yamamoto, M., Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res., 56, 72, 1996.
180. Grinberg-Funes, R. A., Singh, V. N., Perera, F. P., Bell, D. A., Young, T. L., Dickey, C., Wang, L. W., and Santella, R. M., Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathione S-transferase M1 genotype, Carcinogenesis, 15(11), 2449, 1994.
181. Kriek, E., Van Schoeten, F. J., Hillebrand, M. J. X., Van Leeuwen, F. E., Den Engelse, L., De Looff, A. J., and Dijkmans, A. P., DNA adducts as a measure of lung cancer risk in humans exposed to PAH, Environ. Health Persp., 99, 71, 1993.
182. Hoffman, D., Brunneman, K. D., Poropczyk, B., and Djordevic, M. V., Tobacco-specific N-nitrosamines and areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans, J. Tox. Env. Health, 41, 1, 1994.
183. Hecht, S. S., Carmella, S. G., Foiles, P. G., and Murphy, S. E., Biomarkers for human uptake and metabolic activation of tobacco-specific nitrosamines, Cancer Res., 54, 1912, 1994.
184. Foiles, P. G., Akerkar, S. A., Carmella, S. G., Kagan, M. et al., Mass spectrometric analysis of tobacco-specific nitroamine-DNA adducts in smokers and nonsmokers, Chem. Res. Toxicol., 4, 364, 1991.
185. Foiles, P. G., Murphy, S. E., Peterson, L. A., Carmella, S. G., and Hecht, S. S., DNA and hemoglobin adducts as markers of metabolic activation of tobacco-specific carcinogens, Cancer Res., 52(Suppl.), 2698s, 1992.
186. Mustonen, R. and Hemminki, K., 7-Methylguanine levels in DNA of smokers' and non-smokers' total white blood cells, granulocytes and lymphocytes, Carcinogenesis, 13(11), 1951, 1992.
187. Flehinger, B. L., Kimmel, M., Polyck, T., and Melamed, M. R., Screening for lung cancer: the Mayo lung project revisited, Cancer, 72, 1573, 1993.
188. Wilson, V. L., Weston, A., Manchester, D. K., Trivers, G. E., Roberts, D. W., Kadlubar, F. F., Wild, C. P., Montesano, R., Willey, J. C., and Mann, D. L., Alkyl and aryl carcinogen adducts detected in human peripheral lung, Carcinogenesis, 10, 2149, 1989.
189. Lin, D., Lay, J. O., and Bryant, M. S., Analysis of 4-aminobiphenyl-DNA adducts in human urinary bladder and lung.
190. Weston, A., Caporaso, N. E., and Taghizadeh, K., Measurements of 4ABP-hemoglobin adducts in lung cancer cases and controls, Cancer Res., 51, 5219, 1991.
191. Cheng, T. J., Christiani, D. C., Xu, X., Wain, J. C., Wiencke, J. K., and Kelsey, K. T., Glutathione S-transferase μ genotype, diet and smoking as determinants of sister chromatid exchange frequency in lymphocytes, Cancer Epid. Biom. Prev., 4, 535, 1995.
192. Bender, M. A., Preston, R. J., Leonard, R. C., Pyatt, B. E., Gooch, P. C., and Shelby, M. D., Chromosomal aberration and sister chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample, Mutat. Res., 204, 421, 1988.
193. Nordic Study Group, A Nordic data base on somatic chromosome damage in humans, Mutat. Res., 241, 325, 1990.
194. Wiencke, J. K., Pemble, S., Ketterer, B., and Kelsey, K. T., Gene deletion of glutathione S-transferase θ: correlation with induced genetic damage and potential role in endogenous mutagenesis, Cancer Epid. Biom. Prev., 4, 253, 1995.
195. Spitz, M. R. and Hsu, T. C., Mutagen sensitivity as a marker of cancer risk, Cancer Detect. Prev., 18(4), 299, 1994.
196. Cariello, N. F. and Skopek, T. R., In vivo mutation at the human HPRT locus, TIG, 9, 322, 1993.
197. Albertini, R. J., Nicklas, J. A., Fuscoe, J. C., Skopek, T. R., Branda, R. F., and O'Neill, J. P., In vivo mutations in human blood cells: biomarkers for molecular biology, Environ. Health Persp., 99, 135, 1993.
198. Cole, J., Green, M. J. L., James, S. E., Henderson, and L., Cole, H., A further assessment of factors influencing measurements of throguanine-resistant mutant frequency in circulating T-lymphoyctes, Mutat. Res., 204, 493, 1988.
199. Perera, F. P., Dickey, C., Santella, R., O'Neill, J. P., Albertini, R. J., Ottman, R., Tsai, W. Y., Mooney, L. A., Savela, K., and Hemminki, K., Carcinogen-DNA adducts and gene mutation in founding workers with low-level exposure to polycyclic aromatic hydrocarbons, Carcinogenesis, 15, 2905, 1994.
200. 6-methylguanine-DNA methyltransferase in human normal and tumour tissue from brain, lung, and ovary, Cancer Res., 51, 4131, 1991.
201. 6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug in tumor and normal lung of patients with lung cancer, Int. J. Cancer, 59, 629, 1994.
202. 6-alkylguanine-DNA alkyltransferase activity in human lung tissue, Carcinogenesis, 15(8), 1535, 1994.
203. Rodenhuis, S. and Slebos, R. J. C., Clinical significance of ras oncogene activation in human lung cancer, Cancer Res., 52(Suppl.), 2665s, 1992.
204. Reynolds, S. H. and Andersen, M. W., Activation of protooncogenes in human and mouse lung tumors, Environ. Health Persp., 93, 145, 1991.
205. anderson, M. W., Reynolds, S. H., You, M., and Maronpot, R. M., Role of protooncogene activation in carcinogenesis, Environ. Health Persp., 98, 13, 1992.
206. Mills, N. E., Fishman, C. L., Rom, W. N., Dubin, N., and Jacobson, D., Increased prevalence of k-ras oncogene mutations in lung adenocarcinoma, Cancer Res., 55, 1444, 1995.
207. Sugimura, H., Caporaso, N. E., Modali, R. V., and Hoover, R. N., Association of rare alleles of the Harvey ras protooncogene locus with lung cancer, Cancer Res., 50, 1857, 1990.
208. Husgafvel-Pursiainen, Ridanpaa, M., Anttila, S., and Vainio, H., p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures, J. Occ. Env. Med., 37(1), 69, 1995.
209. Yakubovskaya, M. S., Spiegelman, V., Luo, F. C., and Malaev, S., Et al., High frequency of k-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer, Int. J. Cancer, 63, 810, 1995.
210. Mao, L., Hruban, R. H., Boyle, J. O., Tockman, M., and Sidransky, D., Detection of oncogene mutations in sputum precedes diagnosis of lung cancer, Cancer Res., 54, 1634, 1994.
211. Brandt-Rauf, P. W., Smith, S. J., and Perera, F. P., Molecular epidemiology and environmental carcinogenesis of the lung, Probl. Resp. Car., 3, 44, 1990.
212. Weissfield, J. L., Larsen, R. D., Niman, H. L., and Kuller, L. H., Evaluation of oncogene-related proteins in serum, Cancer Epid. Biom. Prev., 3, 57, 1994.
213. Sugio, K., Kishimoto, Y., Virmani, A. K., Hung, J., and Gazdar, A. F., K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas, Cancer Res., 54(22), 5811, 1994.
214. Li, Z-H., Zheng, J., Weiss, L. M., and Shibata, D., c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung, Am. J. Pathol., 144(2), 303, 1994.
215. Rodenhuis, S. and Slebos, R. J. C., Clinical significance of ras oncogene activation in human lung cancer, Cancer Res., 52, 2665s, 1992.
216. Ryberg, D., Tefre, T., Skaug, V., Stangeland, L., Ovrebo, S., Naalsund, A., Borresen, A. L., and Haugen, A., Allele diversity of the h-ras-1 variable number of tandem repeats in Norwegian lung cancer patients, Environ. Health Persp., 98, 187, 1992.
217. Krontiris, T. G., Devlin, B., Karp, D. D., Robert, N. J., and Risch, N., An association between the risk of cancer and mutations in the h-ras-1 minisatellite locus, NEJM, 329(8), 518, 1993.
218. Brandt-Rauf, P. W., Luo, J. C., Carney, W. P., Smith, S., DeVivo, I., Milling, C., Hemminki, K., Koskinen, H., Vainio, H., and Neugut, A. I., Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans, Int. J. Cancer, 56, 383, 1994.
219. Shi, D., He, G., Cao, S., Pan, W., Zhang, H. Z., Yu, D., and Hung, M. C., Overexpression of the c-erhB-2/neu-encoded p185 protein in primary lung cancer, Mol. Carcinogen., 5, 213, 1992.
220. Paako, P., Nuorva, K., Kamel, D., and Soini, Y., Evidence by in situ hybridization that c-erbB- 2 protooncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas. Am. J. Resp. Cell. Mol. Biol., 7, 325, 1992.
221. King, C. R., Krauss, M. H., DiFiore, P. P., Paik, S., and Kaspryzk, P. G., Implications of erbB-2 overexpression for basic science and clinical medicine, Semin. Cancer Biol., 1, 329, 1990.
222. Gazzeri, S., Brambilla, E., De Fromentel, C., Gouyer, V., Moro, D., Perron, P., Berger, F., and Brambilla, C., p53 genetic abnormalities and myc activation in human lung carcinoma, Int. J. Cancer, 58, 24, 1994.
223. Pfeifer, A. M. A., Jones, R. T., Bowden, P. E., Mann, D., Spillare, E., Klein-Szanto, A. J., Trump, B. F., and Harris, C. C., Human bronchial epithelial cells transformed by the c-raf-1 and c-myc protooncogenes induce multidifferentiated carcinomas in nude mice: a model for lung carcinogenesis, Cancer Res., 51, 3793, 1991.
224. Broers, J. L., Viallet, J., Jensen, S. M., Pass, H., Travis, W. D., Minna, J. D., and Linnoila, R. I., Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am. J. Resp. Cell Mol. Biol., 9, 33, 1993.
225. Weston, A., Ling-Cawley, H., Caparoso, N. E., Bowman, E. D., Hoover, R. N., Trump, B. F., and Harris, C. C., Determination of the allelic frequen- cies of an L-myc and a p53 polymorphism in human lung cancer, Carcinogenesis, 15(4), 583, 1994.
226. Schauer, I. E., Siriwardana, S., Langan, T. A., and Sclafani R. A., Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer, Proc. Natl. Acad. Sci. U.S.A., 91, 7827, 1994.
227. Morgan, D. O., Principles of CDK regulation, Nature, 374, 131, 1995.
228. Hollingsworth, R. E., Jr., Chen, P. L., and Lee, W. H., Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein, Curr. Opin. Cell. Biol., 5(2), 194, 1993.
229. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., DeFazio, A., Watts, C. K., Musgrove, E. A., and Sutherland, R. L., Expression and amplification of cyclin genes in human breast cancer, Oncogene, 8(8), 2127, 1993.
230. Jiang, W., Zhang, Y-J., Kahn, S. M., Hollstein, M. C., Santella, R. M., Lu, S. H., Harris, C. C., Montesano, R., and Weinstein, I. B., Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer, Proc. Natl. Acad. Sci. U.S.A., 90, 9026, 1993.
231. Zhang, Y-J., Jiang, W., Chen, C. J., Lee, C. S., Kahn, S. M., Santella, R. M., and Weinstein, I. B., Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma, Biochem. Biophys. Res. Comm., 196, 1010, 1993.
232. Betticher, D. C., Thatcher, N., Altermatt, H. J., Hoban, P., Ryder, W. D., and Heighway, J., Alternate splicing produces a novel cyclin D1 transcript, Oncogene, 11, 1005, 1995.
233. Keyomarsi, K., Conte, D., Toyofuku, W., and Fox, M. P., Deregulation of cyclin E in breast cancer, Oncogene, 11, 941, 1995.
234. Harris, C. C. and Hollstein, M., Clinical implications of the p53 tumor-suppressor gene, N. Engl. J. Med., 329(18), 1318, 1993.
235. Birrer, M. J. and Brown, P. H., Application of molecular genetics to the early diagnosis and screening of lung cancer, Cancer Res., (S52), 2658s, 1992.
236. Levin, W. L., Casey, G., Ramos, J., Arboleda, M. J., Reissman, P. T., and Slamon, D. J., Tumor suppressor and immediate early transcription factor genes in NSC lung cancer, Chest, 106(6S), 372, 1994.
237. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D., Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53, Cell, 70, 937, 1992.
238. Kastan, M. B., Onyekewere, O., Sidransky, D., Vogelstein, B., and Craig, R. W., Participation of p53 protein in the cellular response to DNA damage, Cancer Res., 51, 6304, 1991.
239. Caelles, C., Helmberg, A., and Karin, M., p53-dependent apoptosis in the absence of transcriptional activation of p-53 target genes, Nature, 370(370), 220, 1994.
240. Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., Wu, M., and Welsh, D., The 1993 Walter Hubert Lecture: the role of the p53 tumorsuppressor gene in tumorigenesis, Br. J. Cancer, 69, 409, 1994.
241. Srivastava, S., Zou, Z. Q., Piollo, K., Blattner, W., and Chang, E. H., Germ-line transmission of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome, Nature, 348, 747, 1990.
242. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L., Increased expression of mutant forms of p53 oncogene in primary lung cancer, Lancet, 335, 675, 1990.
243. Bennett, W. P., p53 alterations in progenitor lesions of the bronchus, esophagus, oral cavity and colon, Cancer Detect. Prev., 19, 503, 1995.
244. Melhem, M. F., Law, J. C., El Ashmawy, L., Johnson, J. T., Landreneau, R. J., Srivastava, S., and Whiteside, T. L., Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers, Am. J. Pathol., 146(5), 1170, 1995.
245. Fujino, M., Dosaka-Akita, H., Kato, M., Kinoshita, I., Akie, K., and Kawakami, Y., Simultaneous use of the PC-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer, Am. J. Clin. Pathol., 104(3), 319, 1995.
246. Top, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R., Visser, S., and Rodenhuis, S., Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell cancer, Int. J. Cancer (Pred. Oncol.), 64, 83, 1995.
247. Lane, D. P., p53, guardian of the genome, Nature, 358, 15, 1992.
248. Hirano, T., Franzen, B., Kato, H., Ebihara, Y., and Auer, G., Genesis of Squamous cell lung carcinoma: sequential changes of proliferation, DNA ploidy and p53 expression, Am. J. Pathol., 144(2), 1994.
249. Westra, W. H., Offerhaus, G. J., Goodman, S. N., Slebos, R. J., Polak, M., Baas, I. O., Rodenhuis, S., and Hruban, R. H., Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking, Am. J. Surg. Pathol., 17, 213, 1993.
250. Taylor, J. A., Watson, M. A., Devereux, T. R., Michels, R. Y., Saccomanno, G., and Anderson, M., p53 mutation hotspot in radon-associated lung cancer, Lancet, 343, 86, 1994.
251. Nuorva, K., Makitaro, R., Huhti, E., Kamel, D., Vahakangas, K., Bloigu, R., Soini, Y., and Paakko, P., p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke, Am. J. Resp. Crit. Care Med., 159, 528, 1994.
252. Dosaka-Akita, H., Shindoh, M., Fujino, M., Kinoshita, I., Akie, K., Katoh, M., and Kawkami, Y., Abnormal expression in human lung cancer is associated with histologic subtypes and patient smoking history, Am. J. Clin. Pathol., 102(5), 660, 1994.
253. Wang, X., Christiani, D. C., Wiencke, J. K., Fischbein, M., Xu, X., Cheng, T. J., Mark, E., Wain, J. C., and Kelsey, K. T., Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure, Cancer Epid. Biom. Prev., 4, 543, 1995.
254. Ryberg, D., Kure, E., Lystad, S., Skaug, V., Stangeland, L., Mercy, I., Borresen, A. L., and Haugen, A., P53 mutations in lung tumors: relationship to putative susceptibility markers for cancer, Cancer Res., 54, 1551, 1994.
255. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U., Della Porta, G., and Pierotti, M. A., Deletions of 17p and p53 mutations in preneoplastic lesions of the lung, Cancer Res., 52, 6079, 1992.
256. Walker, C., Robertson, L. J., Myskow, M. W., Pendleton, N., and Dixon, G. R., p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas, Br. J. Cancer, 70, 297, 1994.
257. Kerr, K. M., Carey, F. A., King, G., and Lamb, D., Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53 and c-erbB-2 expression, J. Pathol., 174, 249, 1994.
258. Nuorva, K., Soini, Y., and Kamel, D., Autio-Harmainen H., Risteli, L., Risteli, J., Vahakangas, K., and Paakko, P., Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas, Am. J. Pathol., 142(3), 1993.
259. Fontanini, G., Vignata, S., Bigini, D., Merlo, G. R., Ribecchini, A., Angeletti, C. A., Basolo, F., Pingitore, R., and Bevilacqua, G., Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression, J. Pathol., 174, 23, 1994.
260. Kawajiri, K., Watanbe, J., Eguchi, H., and Hayashi, S., Genetic polymorphims of drug-metabolizing enzymes and lung cancer susceptibility, Phannacogenetics, 5, S70, 1995.
261. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., and Hayashi, S. I., Germ line polymorphism of p53 and CYP1A1 genes involved in human lung cancer, Carcinogenesis, 14(6), 1085, 1993.
262. Jin, X., Wu, X., Roth, J. A., Amos, C. I., King, T. M., Branch, C., Honn, S. E., and Spitz, M. R., Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype, Carcinogenesis, 16(9), 2205, 1995.
263. Birgander, R., Sjalander, A., Rannug, A., Alexandrie, A. K., Sundberg, M. I., Seidegard, J., Tornling, G., Beckman, G., and Beckman, L., P53 polymorphisms and haplotypes in lung cancer, Carcinogenesis, 16(9), 2233, 1995.
264. Sasche, R., Murakami, Y., Shiraishi, M., Hayashi, K., and Sekiya, T., DNA aberrations at the retinoblastoma gene loci in human squamous cell carcinomas of the lung, Oncogene, 9(1), 39, 1994.
265. Dean, D. C., Weintraub, S. J., and Holtzman, M. J., A molecular switch between lung development and cancer: is the tumor suppressor Rb turned on during bronchial epithelial cell differentiation and turned off in small cell lung cancer?, Am. J. Respir. Cell Mol. Biol., 11, 249, 1994.
266. Hensel, C. H., Hsieh, C. L., Gazdar, A. F., Johnson, B. E., Sakaguchi, A. Y., Naylor, S. L., Lee, W. H., and Lee, E. Y., Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer, Cancer Res., 50, 3067, 1990.
267. Livingston, D. M., Kaelin, W., Chittenden, T., and Qin, X., Structural and functional contributions to the G1 blocking action of the retinoblastoma protein, Br. J. Cancer, 68, 264, 1993.
268. Ookawa, K., Shiseki, M., Takahashi, R., Yoshida, Y., Terada, M., and Yokota, J., Reconstitution of the Rb gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations, Oncogene, 8(8), 2175, 1993.
269. Hiyama, K., Ishioka, S., Shirotani, Y., and Inai, K., Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb, Oncogene, 10(5), 937, 1995.
270. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J., Reciprocal Rb inactivation and p16INK expression in primary lung cancers and cell lines, Cancer Res., 55(3), 505, 1995.
271. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J., Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type Rb, Oncogene, 9(11), 3375, 1994.
272. Reissman, P. T., Koga, H., Takahashi, R., Figlin, R. A., Holmes, E. C., Piantadosi, S., Cordon-Cardo, C., and Slamon, D. J., Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer, Oncogene, 8(7), 1913, 1993.
273. Clements, N. C., Nelson, M. A., Wymer, J. A., Savage, C., Aguirre, M., and Garewal, H., Analysis of k-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy, Am. J. Respir. Crit. Care. Med., 152, 1374, 1995.
274. Mills, N. E., Fishman, C. L., Scholes, J., anderson, S. E, Rom, W. N., and Jacobson, D. R., Detection of k-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis, J. Natl. Cancer Inst., 87(14), 1401, 1995.
275. Rothman, N., Stewart, W. F., and Schulte, P. A., Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories, Cancer Epid. Biom. Prev., 4, 301, 1995.
276. Schulte, P. A., Biomarkers in epidemiology: scientific issues and ethical implications, Environ. Health Persp., 98, 143, 1992.
277. Tockman, M. S., Gupta, P. K., Pressman, N. J., and Mulshine, J. L., Considerations in bringing a cancer biomarker to clinical application, Cancer Res., 52(Suppl.), 2711s, 1992.
278. Overview: NCI workshop on investigational strategies for detection and intervention in early lung cancer, Cancer Res., 52(Suppl.), 2639s, 1992.
279. Hirvonen, A., Genetic factors in individual responses to environmental exposures, J. Occ. Environ. Med., 37(1), 37, 1995.
280. Vineis, P. and Caporaso, N., Tobacco and cancer: epidemiology and the laboratory, Environ. Health Persp., 103(2), 156, 1995.
281. Birrer, M. J., Translational research and epithelial carcinogenesis: molecular diagnostic assays now -molecular screening assays soon?, J. Natl. Cancer Inst., 87(14), 1041, 1995.
282. Hasday, J. D. and McCrea, K. A., Inherited predisposition to lung cancer, Occ. Med. State of the Art Reviews, 7(2), 227, 1992.
283. Raunio, H. and Pelkonen, O., Genetic factors in the activation and inactivation of chemical carcinogens, in Drugs, Diet and Disease. I. Mechanistic Approaches to Cancer, Ioannides, Ed., Ellis Horwood Ltd, New York, 1995, 229.
284. Parke, D. V., The cytochromes P450 and mechanisms of chemical carcinogenesis, Environ. Health Persp., 102(10), 852, 1994.
285. Soderkvist, P. and Axelson, O., On the use of molecular biology data in occupational and environmental epidemiology, J. Occ. Environ. Med., 37(1), 84, 1995.
286. Boers, J. E., Ten Velde, G. P. M., and Thunnisen, B. J. M., P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma, Am. J. Respir. Crit. Care Med., 153, 411, 1996.
287. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., Takahashi, T., and Ueda, R., p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52, 734, 1992.
288. Horsmans, Y., Desager, J. P., and Harvengl, C., Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?, Biomed. Pharmacother., 45, 359, 1991.
289. Kerb, R., Brockmoller, J., and Drakoulis, N., CYP2D6 and glutathione S-transferase class mu as host factors of lung cancer susceptibility, J. Basic Clin. Physiol. Pharmacol., 3, 131, 1992.
290. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunhill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y., bcl-2 protein in non-small cell lung carcinoma, N. Engl. J. Med., 329, 690, 1993.
291. Kitagawa, Y., Wong, F., Lo, P., Elliot, M., Verburgt, L. M., Hogg, J. C, and Daya, M., Overexpression of bcl-2 and mutations in p53 and k-ras in resected human non-small cell lung cancers. Am. J. Respir. Cell Mol. Biol., 15, 45, 1996.
292. Dosaka-Akita, H., Akie, K., Hiroumi, H., Kinoshita, I., Kawakami, Y., and Murakami, A., Inhibition of proliferation by L-myc antisense DNA for the transla- tional initiation site in human small cell lung cancer, Cancer Res. 55(7), 1559, 1995.
293. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H., and Tateishi, R., High prevalence of bcl-2 oncoprotein expression in small cell lung cancer, Anticancer Res., 15(2), 503, 1995.
294. Reeve, J. G, Xiong, J., Morgan, J., and Bleehen, N. M., Expression of apoptosis-regulatory genes in lung tumor cell lines: relationship to p53 expression and relevance to acquired drug resistance, Br. J. Cancer, 73(10), 1193, 1996.
295. Murata, M., Tagawa, M., Kimura, M., Kimura, H., Watanabe, S., and Saisho H., Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history, Carcinogenesis, 17(2), 261, 1996.
296. Devereux, T. R., Taylor, J. A., and Barrett, J. C., Molecular mechanisms of lung cancer, CHEST, 109(3)Suppl, 14S, 1996.
297. Gariboldi, M., Manenti, G., Canzian, F., Falvella, F. S., Radice, M. T., Pierotti, M. A., Della Porta, G., Binelli, G., and Dragani, T. A., A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6, Nature Genet., 3(2), 132, 1993.
298. Devereux, T. R., Wiseman, R. W., Kaplan, N., Garren, S., Foley, J. F, White, C. M., Anna, C., Watson, M. A., Patel, A., and Jarchow, S., Mammalian Genome, 5(12), 749, 1994.
299. Festing, M., Yang, A., and Malkinson, A. M., At least four genes and sex are associated with susceptibility to urethane-induced pulmonary adenomas in mice, Genet. Res., 64, 99, 1994.
300. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C., Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res., 54, 4855, 1994.
301. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigan, S. V., Stockert, E., Day, R. S., 3rd, Johnson, B. E., and Skolnick, M. H., A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264(5157), 436, 1994.
302. Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., Van der Riet, P., Blaugrand, J. E., and Sidransky, D., Rates of p16 (MTS1) mutations in primary tumors with 9p loss (letter), Science, 265(5170), 415, 1994.
303. Serrano, M., Hannon, G. J., and Beach, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4, Nature, 366, 704, 1993.
304. INK4B is a potential effector of TGF-β-induced cell cycle arrest, Nature, 371, 257, 1994.
305. Rosvold, E. A., McGlynn, K. A., Lustbader, E. D., and Buetow, K. H., Identification of an NAD(P)h:quinone oxidoreductase polymorphism and its associa- tion with lung cancer and smoking, Pharmacogenetics, 5, 199, 1995.
306. Nelson, M. A., Wymer, J., and Clements, N., Detection of k-ras gene mutations in non-neoplastic lung tissue and lung cancers, Cancer Letters, 103, 115, 1996.
307. Westra, W. H., Baas, I. O., Hruban, R. H., Askin, F. B., Wilson, K., Offerhaus, G. J. A, and Slebos, R. J. C., K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res., 56, 2224, 1996.
308. 6-alkylguanine-DNA alkyltransferase activity in normal human tissues and cells. Cancer Res., 44, 2855, 1984.
309. 6-methylguanine-DNA methyltransferase and uracil DNA glycosylase in human broncho-alveolar lavage cells and peripheral blood mononuclear cells from tobacco smokers and non-smokers, Carcinogenesis, 12, 1389, 1991.
310. Sugimura, H., Caparoso, N. E., Hoover, R. N., Modali, R., Resau, J., Trump, B. F., Lonergan, J. A., Krontiris, T. G., Mann, D. L., Weston, A., and Harris, C. C., Association of rare alleles of the Harvey ras protooncogene locus with lung cancer, Cancer Res., 50, 1857, 1990.
311. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vincour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D., p53: a frequent target for genetic abnormalities in lung cancer. Science, 246, 491, 1989.
312. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B., Mutations in the p53 gene occur in diverse human tumor types, Nature, 342, 705, 1989.
313. Takeshima, Y., Seyama, T., Bennett, W. P., Akiyama, M., Tokuoka, S., Inai, K., Mabuchi, K., Land, C. E., and Harris, C. C., p53 mutations in lung cancers from non-smoking atomic-bomb survivors, Lancet, 342, 1520, 1993.
314. Vahakangas, K. H., Samet, J. M., Metcalf, R. A., Welsh, J. A., Bennett, W. P., Lane, D. P., and Harris, C. C., Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners, Lancet, 339, 576, 1992.
315. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C., Mutations and altered expression of genes regulating the cell cycle G1 checkpoint in human cancer, Proc. Natl. Acad. Sci., U.S.A., 91, 11045, 1994.